OBJECTIVE: To investigate the relative effect of @entity1229 versus non- @entity2067 oral anticoagulants (NOACs) in @entity715 and @entity548 outcomes in subgroups of @entity955 ( @entity955 ) @entity1 with varying degrees of @entity8 . METHODS: Systemic review and meta-regression analyses on NOACs versus @entity1229 , supplemented with indirect comparisons were conducted. The eligibility criteria for inclusion were randomised controlled trials comparing NOACs against @entity1229 for @entity64 prevention in @entity955 @entity1 . Outcomes of interest were @entity64 or @entity887 ( @entity887 ) and major @entity548 . RESULTS: Five studies comprising 72,845 @entity955 @entity1 randomised to either a NOAC or @entity1229 were included in the meta-regression analysis. A shift in strata from no @entity8 to @entity8 resulted in a non-significant impact on @entity548 and @entity64 / @entity887 , indicating similar safety and efficacy, despite renal function status. Apixaban was associated with less major @entity548 compared to @entity3926 and @entity3925 but not @entity14242 in @entity1 with moderate @entity8 . For efficacy outcomes, only @entity3926 150  mg was statistically significantly favoured compared to @entity14242 30  mg. For efficacy outcomes in mild @entity8 , both @entity3926 150  mg and @entity3925 10  mg (J-ROCKET) were statistically significantly favoured against @entity14242 30  mg. CONCLUSION: Non- @entity2067 oral anticoagulants had similar efficacy and safety compared to @entity1229 across different levels of renal function. Indirect comparisons suggest that @entity5424 and @entity14242 were associated with a better safety profile in @entity1 with moderate @entity8 . However, caution is warranted when interpreting indirect comparisons of drugs investigated in different trials. Prescribers should fit the most appropriate NOAC to the @entity955 @entity1 characteristics (and vice versa) to individualise effective @entity64 prevention.

Renal function and non- @entity2067 oral anticoagulants in comparison with @entity1229 on safety and efficacy outcomes in @entity955 XXXX : a systemic review and meta-regression analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal dysfunction'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity887 :: ('MESH:D004617', 'Disease') :: ['SE', 'systemic embolism'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity14242 :: ('MESH:C552171', 'Chemical') :: ['edoxaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1 :: (9606,Species) :: ['patients']
